Key result
Intracoronary infusion of wild-type mesenchymal stem cells improved postischemic left ventricular function and reduced proapoptotic and proinflammatory signaling via a STAT3-dependent mechanism.
Why the study?
Does intracoronary infusion of wild-type MSCs improve postischemic myocardial functional recovery and reduce inflammation and apoptosis compared to STAT3 knockout MSCs or vehicle in a rat model of ischemia/reperfusion?
Does intracoronary infusion of wild-type MSCs improve postischemic myocardial functional recovery and reduce inflammation and apoptosis compared to STAT3 knockout MSCs or vehicle in a rat model of ischemia/reperfusion?
Intracoronary infusion of mesenchymal stem cells improves postischemic left ventricular function and reduces proapoptotic and proinflammatory signaling via a STAT3-dependent mechanism in a preclinical model.
STAT3-dependent MSC effects merit targeted in vivo validation in ischemia; leaves open any clinical translation.
BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) regulates myocardial apoptosis, cellular proliferation, and the immune response after ischemia/reperfusion (I/R). STAT3 is also necessary for the production of vascular endothelial growth factor (VEGF) by mesenchymal stem cells (MSCs), which are known to reduce myocardial injury after I/R. However, it remains unknown whether STAT3 is an important mediator of MSC-based cardioprotection. We hypothesized that knockout of stem cell STAT3 would reduce MSC-derived myocardial functional recovery and increase myocardial inflammatory and apoptotic signaling. STUDY DESIGN: With a Langendorff apparatus, male rat hearts were subjected to 15 minutes of equilibration and 25 minutes of ischemia, followed by 40 minutes of reperfusion. Immediately before ischemia, hearts received intracoronary infusions of vehicle, wild-type MSCs (WT MSCs) or STAT3 knockout MSCs (STAT3KO MSCs). Heart function was measured continuously. Myocardial homogenates were analyzed for production of interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α). Additionally, MSC production of hepatocyte growth factor (HGF) and insulin-like growth factor-1 (IGF-1) were measured in vitro. RESULTS: Hearts treated with WT MSCs exhibited the greatest functional recovery, and those treated with STAT3KO MSCs had equivalent recovery to vehicle. The highest proinflammatory cytokine levels were seen in vehicle-treated hearts, and the lowest in the WT MSC group. STAT3KO MSCs produced less IGF-1, but more HGF than WT MSCs. Finally, hearts treated with STAT3KO MSCs or vehicle had significantly higher caspase-3 levels than those treated with WT MSCs. CONCLUSIONS: Intracoronary infusions of MSCs improve postischemic left ventricular function and reduce proapoptotic and proinflammatory signaling via a STAT3-dependent mechanism.
No takes yet. Share an insight, caveat, or question.
Poynter et al. (2011) studied Myocardial ischemia/reperfusion injury. Wild-type mesenchymal stem cells (WT MSCs) vs. STAT3 knockout MSCs or vehicle was evaluated on Myocardial functional recovery. Intracoronary infusion of wild-type mesenchymal stem cells improved postischemic left ventricular function and reduced proapoptotic and proinflammatory signaling via a STAT3-dependent mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: